The impact of EBV status on characteristics and outcomes of central nervous system lymphoproliferative disorder

IF 2.9 3区医学 Q2 NEUROSCIENCES

Neuroscience Pub Date : 2025-07-01 DOI:10.1016/j.neuroscience.2025.06.066

Xiaojiao Xu , Xiaowei Xing , Yuheng Shan , Jiahua Zhao , Xiaosa Yang , Rui Liu , Yubao Ma , Jiatang Zhang

{"title":"The impact of EBV status on characteristics and outcomes of central nervous system lymphoproliferative disorder","authors":"Xiaojiao Xu , Xiaowei Xing , Yuheng Shan , Jiahua Zhao , Xiaosa Yang , Rui Liu , Yubao Ma , Jiatang Zhang","doi":"10.1016/j.neuroscience.2025.06.066","DOIUrl":null,"url":null,"abstract":"<div><div>Central nervous system lymphoproliferative disorder (CNS-LPD) is a rare disease of the central nervous system (CNS) with significant misdiagnosis and mortality, and Both EBV-positive (EBVpos) and EBV-negative (EBVneg) cases have been reported. To investigate the relationship between EBV status and the clinical characteristics and outcomes of CNS-LPD patients, we conducted a retrospective cohort study with 39 EBVpos and 41 EBVneg patients with CNS-LPD. EBVpos patients had higher rates of cerebrospinal fluid (CSF) leukocytosis, elevated protein levels, and worse functional outcomes, and no significant difference in survival was found between EBVpos and EBVneg patients. Regression analysis identified ECOG performance status ≥2 as an independent risk factor for overall survival and age ≥60, EBV-positivity, and ECOG performance status ≥2 as independent risk factors for poorer functional prognosis. These findings highlight that different management strategies should be developed for different EBV status patients.</div></div>","PeriodicalId":19142,"journal":{"name":"Neuroscience","volume":"581 ","pages":"Pages 34-39"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306452225007547","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Central nervous system lymphoproliferative disorder (CNS-LPD) is a rare disease of the central nervous system (CNS) with significant misdiagnosis and mortality, and Both EBV-positive (EBVpos) and EBV-negative (EBVneg) cases have been reported. To investigate the relationship between EBV status and the clinical characteristics and outcomes of CNS-LPD patients, we conducted a retrospective cohort study with 39 EBVpos and 41 EBVneg patients with CNS-LPD. EBVpos patients had higher rates of cerebrospinal fluid (CSF) leukocytosis, elevated protein levels, and worse functional outcomes, and no significant difference in survival was found between EBVpos and EBVneg patients. Regression analysis identified ECOG performance status ≥2 as an independent risk factor for overall survival and age ≥60, EBV-positivity, and ECOG performance status ≥2 as independent risk factors for poorer functional prognosis. These findings highlight that different management strategies should be developed for different EBV status patients.

查看原文本刊更多论文

EBV状态对中枢神经系统淋巴细胞增生性疾病特征和预后的影响

中枢神经系统淋巴细胞增生性疾病（Central nervous system lymphoprolifative disorder, CNS- lpd）是一种罕见的中枢神经系统（Central nervous system， CNS）疾病，其误诊率高，死亡率高，ebv阳性（EBVpos）和ebv阴性（EBVneg）病例均有报道。为了探讨EBV状态与CNS-LPD患者临床特征和预后的关系，我们对39例EBVpos患者和41例ebv阴性的CNS-LPD患者进行了回顾性队列研究。EBVpos患者脑脊液（CSF）白细胞增多率较高，蛋白水平升高，功能预后较差，EBVpos患者和ebv阴性患者的生存率无显著差异。回归分析发现ECOG性能状态≥2是影响总生存的独立危险因素，年龄≥60岁，ebv阳性，ECOG性能状态≥2是功能预后较差的独立危险因素。这些发现强调了针对不同EBV状态的患者应制定不同的管理策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroscience 医学-神经科学

CiteScore

6.20

自引率

0.00%

发文量

394

审稿时长

52 days

期刊介绍： Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details.